Revance Therap (RVNC.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Mar31

Crown Laboratories Renamed to Revance, Signifying Major Transformation

13:59

Feb5

Crown Laboratories' acquisition offer for Revance Therapeutics expires, expected to complete transaction in 2025

13:02

Feb4

Levi & Korsinsky, LLP Notifies Investors of Class Action Securities Case Against Revance Therapeutics, Inc.

17:02

Jan31

Crown Laboratories Urges Revance Shareholders to Submit Shares for Acquisition Completion

12:31

Jan23

Bragar Eagel & Squire, P.C. Files Class Action Against BioAge Labs and Revance Therapeutics

02:35

Jan6

Teoxane SA Raises Bid for Revance Therapeutics to $3.60 per Share

15:23

Schedules & Filings

Schedules

Filings

Nov7

Earning Release(EST)

FY2024 Q3 Earning Release (USD) Revenue 59.88 M, Net Income -38.12 M, EPS -0.3657

Aug8

Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 65.39 M, Net Income -37.47 M, EPS -0.3607

May9

Earning Release(EST)

FY2024 Q1 Earning Release (USD) Revenue 51.94 M, Net Income -53.15 M, EPS -0.5782

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change